Compare Aehr Test Systems (AEHR) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs Alnylam Pharmaceuticals, Inc. — how do they compare? Aehr Test Systems trades at $129.04 (market cap $3.82B), while Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.7× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| AEHR | ALNY | |
|---|---|---|
Market Cap | $3.82B | $29.60B |
Sector | Technology | Health |
52-Week High | $117.18 | $491.22 |
52-Week Low | $17.38 | $205.48 |
Enterprise Value | $3.72B | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aehr Test Systems (AEHR) trades at $129.23, up 21.69% in the last 24 hours, reflecting strong momentum. The stock is technically bullish, trading near resistance at $129, with a high RSI suggesting potential overbought conditions. Fundamentally, the company reported a net loss of $3.91 million for 2025, but has beaten EPS estimates for three consecutive quarters. Recent news highlights a $22 million follow-on order for AI processor wafer-level burn-in systems, signaling robust demand in high-growth sectors.
The outlook is supported by record bookings and a strategic pivot to AI infrastructure, though high valuation multiples and insider selling pose risks. Revenue growth guidance of 160-200% for FY27 offers significant upside potential, but investor caution is warranted due to customer concentration and current unprofitability.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
